[go: up one dir, main page]

MX2012012094A - Sintesis novedosa para compuestos de tiazolidinadiona. - Google Patents

Sintesis novedosa para compuestos de tiazolidinadiona.

Info

Publication number
MX2012012094A
MX2012012094A MX2012012094A MX2012012094A MX2012012094A MX 2012012094 A MX2012012094 A MX 2012012094A MX 2012012094 A MX2012012094 A MX 2012012094A MX 2012012094 A MX2012012094 A MX 2012012094A MX 2012012094 A MX2012012094 A MX 2012012094A
Authority
MX
Mexico
Prior art keywords
novel synthesis
thiazolidinedione compounds
compounds
thiazolidinedione
thiazolidinediones
Prior art date
Application number
MX2012012094A
Other languages
English (en)
Inventor
Scott D Larsen
Robert C Gadwood
Steven P Tanis
James R Zeller
Timothy Parker
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of MX2012012094A publication Critical patent/MX2012012094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona métodos novedosos para sintetizar compuestos sustitutos de PPAR?, por ejemplo tiazolidinadionas, que son útiles para evitar y/o tratar trastornos metabólicos tales como diabetes, obesidad, hipertensión y enfermedades inflamatorias.
MX2012012094A 2010-04-19 2011-04-18 Sintesis novedosa para compuestos de tiazolidinadiona. MX2012012094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32552810P 2010-04-19 2010-04-19
PCT/US2011/032816 WO2011133441A2 (en) 2010-04-19 2011-04-18 Novel synthesis for thiazolidinedione compounds

Publications (1)

Publication Number Publication Date
MX2012012094A true MX2012012094A (es) 2012-12-17

Family

ID=44041528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012094A MX2012012094A (es) 2010-04-19 2011-04-18 Sintesis novedosa para compuestos de tiazolidinadiona.

Country Status (10)

Country Link
US (2) US20130211095A1 (es)
EP (1) EP2563767A2 (es)
JP (1) JP2013532121A (es)
KR (1) KR20130051944A (es)
CN (1) CN103153972A (es)
AU (1) AU2011242955A1 (es)
CA (1) CA2796872A1 (es)
MX (1) MX2012012094A (es)
RU (1) RU2012148909A (es)
WO (1) WO2011133441A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
HUE030263T2 (en) 2010-04-19 2017-04-28 Octeta Therapeutics Llc New synthesis for the preparation of thiazolidinedione compounds
RU2594725C2 (ru) 2010-08-10 2016-08-20 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Синтез соединений тиазолидиндиона
EP2603498B1 (en) * 2010-08-10 2016-11-09 Octeta Therapeutics, LLC Novel synthesis for thiazolidinedione compounds
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US10326748B1 (en) 2015-02-25 2019-06-18 Quest Software Inc. Systems and methods for event-based authentication
US10417613B1 (en) 2015-03-17 2019-09-17 Quest Software Inc. Systems and methods of patternizing logged user-initiated events for scheduling functions
US10536352B1 (en) 2015-08-05 2020-01-14 Quest Software Inc. Systems and methods for tuning cross-platform data collection
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579733B1 (en) * 1991-04-11 2001-06-20 PHARMACIA & UPJOHN COMPANY Thiazolidinedione derivatives, production and use thereof
SE9702305D0 (sv) * 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
ES2654908T3 (es) * 2006-03-16 2018-02-15 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica
CN101454006B (zh) * 2006-03-16 2012-12-26 新陈代谢解决方案开发公司 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
JP2009013091A (ja) * 2007-07-03 2009-01-22 Tokuyama Corp ピオグリタゾン塩酸塩の製造方法

Also Published As

Publication number Publication date
WO2011133441A2 (en) 2011-10-27
RU2012148909A (ru) 2014-05-27
US20140018542A1 (en) 2014-01-16
CA2796872A1 (en) 2011-10-27
CN103153972A (zh) 2013-06-12
KR20130051944A (ko) 2013-05-21
JP2013532121A (ja) 2013-08-15
EP2563767A2 (en) 2013-03-06
WO2011133441A3 (en) 2015-09-17
US20130211095A1 (en) 2013-08-15
AU2011242955A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
MX2012012094A (es) Sintesis novedosa para compuestos de tiazolidinadiona.
CY1118187T1 (el) Χημικες ενωσεις
PL2346864T3 (pl) Nowe związki użyteczne do leczenia chorób degeneracyjnych i zapalnych
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
MX351368B (es) Compuestos heteroarilo y metodos para utilizarlos.
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201171063A1 (ru) Фармацевтические составы олмесартана
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
HK1210611A1 (en) Histone demethylase inhibitors
IN2012DN03883A (es)
MY153915A (en) Organic compounds
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
EA201070256A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
ZA201005116B (en) 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
WO2013040227A3 (en) Therapeutic compounds
MX2012012092A (es) Sintesis novedosa para compuestos de tiazolidinadiona.
WO2012082862A3 (en) Androgen receptor inhibitors and methods of use thereof
MX2013001475A (es) Sintesis para compuestos de tiazolidindiona.
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
WO2010148177A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment
MX349006B (es) Nueva sintesis para compuestos de tiazolidindiona.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal